SCHEMBL18136984

SCHEMBL18136984

CCc1cnc(O)c(NS(=O)(=O)c2cccc(C(=O)O)c2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.52
▸ TSHR P16473 1/20 0.52
▸ PTK2B Q14289 1/20 0.52
▸ KMT2A Q03164 4/20 0.51
▸ ALDH1A1 P00352 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ MAPT P10636 1/20 0.48
▸ METAP2 P50579 1/20 0.48
▸ ACLY P53396 1/20 0.47
▸ BRD4 O60885 1/20 0.47
▸ CASP3 P42574 1/20 0.47
▸ SENP8 Q96LD8 1/20 0.47
▸ SENP7 Q9BQF6 1/20 0.47
▸ SENP6 Q9GZR1 1/20 0.47
▸ AKR1C3 P42330 3/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24139854 0.88 KDM4E (0.57) KDM4ETSHRPTK2BKMT2AALDH1A1
SCHEMBL16020309 0.86 ALDH1A1 (0.53) KDM4ETSHRPTK2BKMT2AALDH1A1
SCHEMBL16020314 0.85 KDM4E (0.55) KDM4ETSHRPTK2BKMT2AALDH1A1
SCHEMBL16020322 0.83 KDM4E (0.47) KDM4ETSHRPTK2BKMT2AALDH1A1
SCHEMBL19558648 0.82 KDM4E (0.52) KDM4ETSHRPTK2BKMT2AALDH1A1
SCHEMBL16017553 0.82 KDM4E (0.52) KDM4ETSHRPTK2BKMT2AALDH1A1
SCHEMBL16020318 0.79 AKR1C3 (0.53) KDM4ETSHRPTK2BKMT2AALDH1A1
SCHEMBL24139765 0.78 SLC40A1 (0.56) KMT2AALDH1A1MEN1METAP2ACLY
SCHEMBL24139910 0.78 ALDH1A1 (0.52) KDM4ETSHRPTK2BKMT2AALDH1A1
SCHEMBL16235212 0.75 SLC40A1 (0.58) KDM4ETSHRPTK2BKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160296528-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) 2016-10-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160296528-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS PIM1, PIM3, PIM2 KDM4E 613/4885TSHR 1618/4885PTK2B 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback